NMOSD & MOGAD: New Treatments and Hope for the Future | Patient Community Day 2026 (Part 2)
NMOSD & MOGAD: New Treatments and Hope for the Future | Patient Community Day 2026 (Part 2)
What progress is being made in treating NMOSD and MOGAD, and what does it mean for people living with these rare neuroimmune conditions?
As part of Patient Community Day 2026, we’re pleased to share the second episode in our two-part ECTRIMS Podcast series, exploring the latest research and the perspectives of people living with MS and related neurological conditions.
Host Brett Drummond sits down with Taylor Ann Macey, Director of Patient Engagement at the Sumaira Foundation who lives with NMOSD, and Dr Eoin Flanagan, Professor of Neurology at Mayo Clinic, for a conversation about scientific progress and lived experience.
- What are the challenges of living with a rare neuroimmune condition?
- How are new treatments changing the outlook for NMOSD and MOGAD?
- And why are the voices of people living with a rare condition so important in shaping future research?
From the isolation that can come with a rare diagnosis to the growing optimism around treatment and research, this conversation highlights both the challenges and the possibilities ahead.
>> Learn more about Patient Community Day.
This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.